Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)

Haemophilia

Volumn 8, Issue SUPPL. 2, 2002, Pages 19-22

  Giangrande, P L F ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Factor VIII; Haemophilia; Inhibitor; PUP; Sucrose formulation; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; HUMAN ALBUMIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG PURIFICATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROENTERITIS; HEMOPHILIA A; HOME CARE; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; MUTATION; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; INFANT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 17944404210     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-8216.2001.00133.x     Document Type: Article

References (9)

1. Sucrose formulated recombinant human antihemophilic fdector VIII is safe and efficacious for treatment of hemophilia A in home therapy
2. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
3. Factor VIII gene inversions in severe hemophilia A patients
4. Haemophilia A. mutation type determines risk of inhibitor formation
5. Emerging issues in blood safety
6. Transfusion transmissible infections
7. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
8. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A. conclusions of a 5-year study of home therapy
9. Incidence of inhibitors in haemophilia A patients - A review of recent studies of recombinant and plasma-derived factor VIII concentrates